<DOC>
	<DOCNO>NCT01670669</DOCNO>
	<brief_summary>The purpose study characterize efficacy , safety , tolerability , steady-state plasma level once-daily oral dose prucalopride ( R108512 ) solution , 0.01 mg/kg 0.03 mg/kg , give paediatric subject functional faecal retention ( FFR ) 8 week . Hypothesis : Pharmacokinetic profile prucalopride paediatric subject expect resemble adult pharmacokinetic profile . Safety tolerability profile expect resemble adult profile .</brief_summary>
	<brief_title>Prucalopride Paediatric Subjects , With Functional Faecal Retention</brief_title>
	<detailed_description>This multicentre , open-label trial paediatric subject ( age 4 12 year ) FFR administer prucalopride oral solution daily 8 week . Subjects enter extension trial complete PRU-USA-12 , single-dose pharmacokinetic trial , usually within previous week . Evaluations efficacy , safety tolerability perform , plasma sample analysis prucalopride level obtain 2 , 4 , 6 8 week . The initial dosage prucalopride oral solution 0.02 mg/kg/day . Dependent subject 's response , parent could adjust dosage within range 0.01 mg/kg/day 0.03 mg/kg/day .</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<criteria>Subject complete PRUUSA12 pharmacokinetic trial Subject bowels `` cleanedout '' ( ie , faecal impaction remove ) Written informed consent , sign subject 's legal guardian investigator Subject assent document form notetofile subject 's source documentation â€¢ No exclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>